MX340360B - Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas. - Google Patents

Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas.

Info

Publication number
MX340360B
MX340360B MX2011010415A MX2011010415A MX340360B MX 340360 B MX340360 B MX 340360B MX 2011010415 A MX2011010415 A MX 2011010415A MX 2011010415 A MX2011010415 A MX 2011010415A MX 340360 B MX340360 B MX 340360B
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulations
making
methods
derivatives
nitrocatechol derivatives
Prior art date
Application number
MX2011010415A
Other languages
English (en)
Other versions
MX2011010415A (es
Inventor
Teofilo Cardoso De Vasconcelos
Ricardo Jorge Dos Santos Lima
Rui Cerdeira De Campos Costa
Original Assignee
Bial-Portela & Ca S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bial-Portela & Ca S A filed Critical Bial-Portela & Ca S A
Publication of MX2011010415A publication Critical patent/MX2011010415A/es
Publication of MX340360B publication Critical patent/MX340360B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

La presente descripción se refiere a composiciones y formulaciones farmacéuticas que comprenden por lo menos un ingrediente farmacéutico activo seleccionado de derivados de nitrocatecol de la fórmula I como se definen en este documento y sales, ésteres, hidratos, solvatos y derivados de los mismos y métodos para hacer las composiciones y formulaciones farmacéuticas.
MX2011010415A 2009-04-01 2010-03-31 Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas. MX340360B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16577809P 2009-04-01 2009-04-01
PCT/PT2010/000014 WO2010114404A1 (en) 2009-04-01 2010-03-31 Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof

Publications (2)

Publication Number Publication Date
MX2011010415A MX2011010415A (es) 2012-03-26
MX340360B true MX340360B (es) 2016-07-07

Family

ID=42225014

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011010415A MX340360B (es) 2009-04-01 2010-03-31 Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas.

Country Status (16)

Country Link
US (4) US9132094B2 (es)
EP (1) EP2413912B1 (es)
JP (2) JP5864409B2 (es)
KR (4) KR20120027197A (es)
CN (2) CN102448444B (es)
AU (1) AU2010231961B2 (es)
BR (1) BRPI1014865B1 (es)
CA (1) CA2757411C (es)
DK (1) DK2413912T3 (es)
ES (1) ES2730678T3 (es)
MX (1) MX340360B (es)
PL (1) PL2413912T3 (es)
PT (1) PT2413912T (es)
RU (2) RU2011144145A (es)
TR (1) TR201908590T4 (es)
WO (1) WO2010114404A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20110713A1 (it) 2011-04-29 2012-10-30 Bracco Imaging Spa Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
ITMI20022394A1 (it) 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
WO2007013830A1 (en) 2005-07-26 2007-02-01 Portela & Ca. S.A. Nitrocatechol derivatives as comt inhibitors
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
LT2481410T (lt) 2007-01-31 2016-11-10 Bial - Portela & Ca., S.A. Nitrokatecholio dariniai kaip komt inhibitoriai vartojami konkrečiu dozavimo režimu
MX2010009610A (es) 2008-03-17 2010-09-30 Bial Portela & Ca Sa Formas de cristal de 5-[3-(2,5-dicloro-4,6-dimetil-1-oxi-piridin-3 -il)-[1,2,4]oxadiazol-5-il]-3-nitrobenceno-1,2-diol.
CA2757411C (en) 2009-04-01 2017-06-27 Teofilo Cardoso De Vasconcelos Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
US20140045900A1 (en) * 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
SI2694471T1 (sl) * 2011-04-08 2017-12-29 Bracco Imaging S.P.A. Postopek priprave sulfatiranega derivata 3,5-dijodo-O-(3-jodofenil)-L-tirozina
ES2758659T3 (es) 2011-12-13 2020-05-06 BIAL PORTELA & Cª S A Compuesto químico útil como intermediario para preparar un inhibidor de catecol-o-metiltransferasa
RU2017120184A (ru) 2014-11-28 2018-12-28 БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. Лекарства для замедления течения болезни паркинсона
US20200170291A1 (en) * 2017-05-23 2020-06-04 Particle Dynamics International, Llc Processes for producing lactitol granulates and granulates produced thereby
US20210338651A1 (en) 2018-10-05 2021-11-04 Neurocrine Biosciences, Inc. Methods for the administration of comt inhibitors
WO2020072884A1 (en) 2018-10-05 2020-04-09 Neurocrine Biosciences, Inc. Methods for the administration of comt inhibitors
US20230147302A1 (en) 2020-03-13 2023-05-11 Bial - Portela & Ca, S.A. Particle size control
GB202011709D0 (en) 2020-07-28 2020-09-09 Bial Portela & Ca Sa Solid dispersion of opicapone
GB202016425D0 (en) 2020-10-16 2020-12-02 Bial Portela & Ca Sa Treatment regimens for parkinson's disease
KR20230118933A (ko) 2020-12-17 2023-08-14 바이알 - 포르텔라 앤드 씨에이 에스에이 초기 특발성 파킨슨병에 대한 치료 요법

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1532178A (en) * 1921-07-25 1925-04-07 Louis A Godbold Lubricator
FR1260080A (fr) 1960-03-22 1961-05-05 Materiel De Forage Soc De Fab Trépan à molettes étanche
IL31990A (en) * 1968-04-26 1974-05-16 Chinoin Gyogyszer Es Vegyeszet Pyridyl 1,2,4-oxadiazole derivatives,process for the preparation thereof and pharmaceutical compositions containing same
US4022901A (en) 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
US4085563A (en) * 1977-01-31 1978-04-25 Campbell Soup Company Cookie dispensing apparatus
US4264573A (en) * 1979-05-21 1981-04-28 Rowell Laboratories, Inc. Pharmaceutical formulation for slow release via controlled surface erosion
US4386668A (en) 1980-09-19 1983-06-07 Hughes Tool Company Sealed lubricated and air cooled rock bit bearing
US4368668A (en) * 1981-05-15 1983-01-18 Veb Kombinat Polygraph "Werner Lamberz" Leipzig Printing plate mounting arrangement
DK175069B1 (da) 1986-03-11 2004-05-24 Hoffmann La Roche Pyrocatecholderivater
US5236952A (en) * 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
YU213587A (en) * 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
DE3840954A1 (de) 1988-12-05 1990-06-07 Shell Int Research Herstellung von 2-chlornicotinsaeureestern
US5206372A (en) 1990-06-05 1993-04-27 Shell Research Limited Preparation of 2-chloropyridine derivatives
ATE113202T1 (de) 1990-11-29 1994-11-15 Wei Ming Pharmaceutical Mfg Co Hilfsträger für direkte verpressung.
CA2126976A1 (en) 1991-12-31 1993-07-08 Hisashi Takasugi Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
FR2730322B1 (fr) 1995-02-02 1997-04-30 Imago Monture de lunettes metallique
US6361794B1 (en) 1996-06-12 2002-03-26 Basf Corporation Method of making ibuprofen and narcotic analgesic composition
DE19628617A1 (de) 1996-07-16 1998-01-22 Basf Ag Direkttablettierhilfsmittel
US6206110B1 (en) * 1996-09-09 2001-03-27 Smith International, Inc. Protected lubricant reservoir with pressure control for sealed bearing earth boring drill bit
HUP0101954A3 (en) 1998-03-27 2002-09-30 Upjohn Co Use of cabergoline in the production of pharmaceutical compositions for the treatment of restless legs syndrome
JP2002526482A (ja) * 1998-09-18 2002-08-20 バーテックス ファーマシューティカルズ インコーポレイテッド ｐ３８のインヒビター
GB2344819A (en) * 1998-12-18 2000-06-21 Portela & Ca Sa 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
IL131037A (en) 1999-07-22 2004-06-20 Israel Atomic Energy Comm Method for making threedimensional photonic band-gap crystals
CZ2002599A3 (cs) 1999-08-19 2002-06-12 Nps Pharmaceuticals Inc. Heteropolycyklické sloučeniny a jejich pouľití jako antagonistů metabotropního receptoru glutamátu
US6660753B2 (en) * 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
JP3850189B2 (ja) * 1999-10-13 2006-11-29 信越化学工業株式会社 固形製剤とその製造方法
FI20000635A0 (fi) 2000-03-17 2000-03-17 Orion Yhtymae Oyj COMT-inhibiittoreiden käyttö analgeettina
SE0001438D0 (sv) 2000-04-18 2000-04-18 Axon Chemicals Bv New chemical compounds and their use in therapy
DE10029201A1 (de) * 2000-06-19 2001-12-20 Basf Ag Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung
GB2363792A (en) 2000-06-21 2002-01-09 Portela & Ca Sa Nitrocatechols
EP1329825A4 (en) 2000-08-24 2006-03-22 Sagawa Express Co Ltd CARD PAYMENT PROCEDURE FOR SERVICE FEES RELATING TO PHYSICAL DISTRIBUTION OR TRANSPORT
CN1166626C (zh) 2000-08-30 2004-09-15 李凌松 三或四取代苯基化合物、其制备方法及应用
CA2430485A1 (en) * 2000-11-28 2002-06-06 Zymogenetics, Inc. Cytonkine receptor zcytor19
EP1354603A1 (en) 2000-12-26 2003-10-22 Takeda Chemical Industries, Ltd. Concomitant drugs
US20040097555A1 (en) * 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
KR100891887B1 (ko) 2001-01-29 2009-04-03 시오노기세이야쿠가부시키가이샤 5-메틸-1-페닐-2-(1ｈ)-피리돈을 활성 성분으로서 함유하는의약 제제
CN1853630A (zh) 2001-02-21 2006-11-01 Nps制药公司 杂多环化合物及其在亲代谢的谷氨酸受体拮抗剂中的应用
US6761905B2 (en) * 2001-05-01 2004-07-13 Wei Ming Pharmaceutical Mfg. Co., Ltd. Process for the preparation of direct tabletting formulations and aids
JP2004534779A (ja) 2001-05-30 2004-11-18 エルジー ライフサイエンス リミテッド 疾病治療用プロテインキナーゼ阻害剤
RU2003138074A (ru) * 2001-06-08 2005-02-20 Цитови Инк. (US) Замещенные 3-арил-5-арил-[1,2,4]-оксадиазолы и их аналоги в качестве активаторов каспаз и индукторов апоптоза, а также их применение
US6627646B2 (en) 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
US7872030B2 (en) 2001-07-26 2011-01-18 Merck Patent Gmbh Use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
JP4379853B2 (ja) * 2001-10-05 2009-12-09 惠民製藥股▲分▼有限公司 直接錠剤化用調合物および補助剤の調合方法
AU2003303373B8 (en) * 2002-12-18 2010-06-10 Cytovia, Inc. 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2005006945A2 (en) * 2003-07-03 2005-01-27 The Salk Institute For Biological Studies Methods for treating neural disorders and compounds useful therefor
WO2005013982A1 (en) 2003-08-06 2005-02-17 Vertex Pharmaceuticals Incorporated Aminotriazole compounds useful as inhibitors of protein kinases
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
WO2005030176A1 (en) 2003-09-29 2005-04-07 Novo Nordisk Femcare Ag Improved stability of progestogen formulations
US7300406B2 (en) * 2003-09-30 2007-11-27 Carter Vandette B Medical examination apparatus
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US7531556B2 (en) * 2004-04-28 2009-05-12 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
EP1625849A1 (en) 2004-08-09 2006-02-15 Liconsa, Liberacion Controlada de Sustancias Activas, S.A. Pharmaceutical composition comprising drospirenone and ethynylestradiol
GB0510143D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
JP4717414B2 (ja) * 2004-11-08 2011-07-06 富田製薬株式会社 低融点薬剤含有顆粒、およびこれを用いて製造した錠剤
JP2008519811A (ja) 2004-11-10 2008-06-12 オリオン コーポレーション 下肢静止不能症候群の治療
WO2006061697A1 (en) * 2004-12-06 2006-06-15 Themis Laboratories Private Limited Sulfonylurea compositions and a process for its preparation
WO2006071184A1 (en) 2004-12-28 2006-07-06 Astrazeneca Ab Aryl sulphonamide modulators
US20080051441A1 (en) * 2004-12-28 2008-02-28 Astrazeneca Ab Aryl Sulphonamide Modulators
MX2007013263A (es) 2005-04-26 2008-01-22 Neurosearch As Novedosos derivados oxadiazol y su uso medico.
US20060257473A1 (en) * 2005-05-11 2006-11-16 Porranee Puranajoti Extended release tablet
GB0510139D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
US7553964B2 (en) * 2005-06-03 2009-06-30 Abbott Laboratories Cyclobutyl amine derivatives
JP2007024970A (ja) * 2005-07-12 2007-02-01 Miyakawa:Kk 液晶表示装置の開口効率を上昇させるための樹脂レンズ製造法及びその製造装置
US20090000437A1 (en) * 2005-07-14 2009-01-01 Provo Craft And Novelty, Inc. Methods for Cutting
WO2007013830A1 (en) * 2005-07-26 2007-02-01 Portela & Ca. S.A. Nitrocatechol derivatives as comt inhibitors
FR2889525A1 (fr) * 2005-08-04 2007-02-09 Palumed Sa Nouveaux derives de polyquinoleines et leur utilisation therapeutique.
US20070048384A1 (en) * 2005-08-26 2007-03-01 Joerg Rosenberg Pharmaceutical compositions
EP1954137A4 (en) * 2005-11-18 2008-12-17 Janssen Pharmaceutica Nv 2-KETO-OXAZOLE AS MODULATORS OF FATTY ACID AMIDHYDROLASE
JP4738419B2 (ja) * 2005-11-30 2011-08-03 富士フイルムＲｉファーマ株式会社 アミロイドの凝集及び／又は沈着に起因する疾患の診断薬及び治療薬
US20100285157A1 (en) * 2006-02-20 2010-11-11 Asahi Breweries, Ltd Granules, tablets and method of producing the same
GB0606774D0 (en) 2006-04-03 2006-05-10 Novartis Ag Organic compounds
EP1845097A1 (en) * 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
PE20080906A1 (es) 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina
US20080167286A1 (en) * 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
JP2008162955A (ja) * 2006-12-28 2008-07-17 Chugai Pharmaceut Co Ltd バリン含有高密度顆粒剤
LT2481410T (lt) * 2007-01-31 2016-11-10 Bial - Portela & Ca., S.A. Nitrokatecholio dariniai kaip komt inhibitoriai vartojami konkrečiu dozavimo režimu
AR065802A1 (es) 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
TWI503128B (zh) * 2007-07-31 2015-10-11 Ajinomoto Kk A granule preparation containing an amino acid with excellent taste
CA2696609C (en) 2007-08-27 2017-09-05 Helicon Therapeutics, Inc. Therapeutic isoxazole compounds
EP2213306A4 (en) * 2007-09-19 2012-08-29 Asahi Group Holdings Ltd METHOD FOR PRODUCING GRANULES WITH MATERIAL OF NATURAL ORIGIN SUCH AS AN EXTRACT OF CHINESE ORTHODOX MEDICINE, RAW DRUG EXTRACT, NATURAL MATERIAL EXTRACT, OR MIXTURE THEREOF AND METHOD FOR PRODUCING TABLETS FROM GRANULES
KR20100126452A (ko) * 2008-02-28 2010-12-01 바이알 - 포르텔라 앤드 씨에이 에스에이 난용성 약물용 약학적 조성물
MX2010009610A (es) 2008-03-17 2010-09-30 Bial Portela & Ca Sa Formas de cristal de 5-[3-(2,5-dicloro-4,6-dimetil-1-oxi-piridin-3 -il)-[1,2,4]oxadiazol-5-il]-3-nitrobenceno-1,2-diol.
CA2729288C (en) * 2008-07-29 2017-01-17 Bial - Portela & C.A., S.A. Administration regime for nitrocatechols
US8827197B2 (en) * 2008-11-04 2014-09-09 Microgreen Polymers Inc Apparatus and method for interleaving polymeric roll for gas impregnation and solid-state foam processing
CA2757411C (en) 2009-04-01 2017-06-27 Teofilo Cardoso De Vasconcelos Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
WO2010114405A2 (en) * 2009-04-01 2010-10-07 Bial - Portela & Ca., S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
BR112012018256A8 (pt) 2010-03-04 2017-12-19 Orion Corp método de tratamento de doença de parkinson
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
ES2758659T3 (es) 2011-12-13 2020-05-06 BIAL PORTELA & Cª S A Compuesto químico útil como intermediario para preparar un inhibidor de catecol-o-metiltransferasa

Also Published As

Publication number Publication date
US20180333402A1 (en) 2018-11-22
AU2010231961A1 (en) 2011-11-24
CA2757411A1 (en) 2010-10-07
KR20120027197A (ko) 2012-03-21
CN102448444B (zh) 2016-05-25
JP6239561B2 (ja) 2017-11-29
US10583130B2 (en) 2020-03-10
ES2730678T3 (es) 2019-11-12
CN105878242A (zh) 2016-08-24
JP2012522763A (ja) 2012-09-27
MX2011010415A (es) 2012-03-26
BRPI1014865A2 (pt) 2016-05-03
EP2413912A1 (en) 2012-02-08
PT2413912T (pt) 2019-06-11
CA2757411C (en) 2017-06-27
KR102023255B1 (ko) 2019-09-19
PL2413912T3 (pl) 2019-09-30
RU2016152167A (ru) 2018-12-19
KR102329271B1 (ko) 2021-11-22
DK2413912T3 (da) 2019-06-17
JP5864409B2 (ja) 2016-02-17
US20100256193A1 (en) 2010-10-07
CN102448444A (zh) 2012-05-09
AU2010231961B2 (en) 2015-05-21
KR20180096826A (ko) 2018-08-29
RU2011144145A (ru) 2013-05-10
RU2701731C2 (ru) 2019-10-01
KR20210009441A (ko) 2021-01-26
US20210023067A1 (en) 2021-01-28
KR20170043671A (ko) 2017-04-21
US20150359783A1 (en) 2015-12-17
WO2010114404A1 (en) 2010-10-07
US10071085B2 (en) 2018-09-11
EP2413912B1 (en) 2019-03-13
RU2016152167A3 (es) 2018-12-19
BRPI1014865B1 (pt) 2020-03-17
US9132094B2 (en) 2015-09-15
TR201908590T4 (tr) 2019-07-22
JP2015232030A (ja) 2015-12-24

Similar Documents

Publication Publication Date Title
MX2011010415A (es) Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas.
MX361618B (es) Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para hacer las mismas.
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MD4556C1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
IN2014MN02598A (es)
EP2613782A4 (en) INDAZOLE DERIVATIVES AS INHIBITORS OF THE ERK PATHWAY
IN2014CN04530A (es)
GEP20227397B (en) Inhibitors of influenza viruses replication
MY183312A (en) Pharmaceutical formulation
WO2011153157A3 (en) Benzoquinolone inhibitors of vmat2
JO3577B1 (ar) صيغ صيدلانية تشمل مشتقات 1-(بيتا-d- غلوكوبيرانوسيل) -2-ثينيل ميثيل بنزين كمثبطات sglt
MX342212B (es) Inhibidores de neprilisina.
MX2011012523A (es) Esteres cetalicos de anhidropentitoles y usos de los mismos.
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
MX2013001677A (es) Formulaciones estables de linaclotida.
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
BR112012011328A2 (pt) inibidores de akt
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
MX2011007267A (es) Composiciones farmaceuticas que comprenden derivados de 2-oxo-1-pirrolidina.
MX2011007451A (es) Composiciones farmaceuticas que comprenden derivados de 2-oxo-1 pirrolidina.
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
IN2012DN04868A (es)
TN2012000105A1 (en) Spirolactam derivatives and uses of same
EA201270302A1 (ru) Безводные формы производных пиридина
WO2011123524A3 (en) Macrolide inhibitors of mtor

Legal Events

Date Code Title Description
FG Grant or registration